Disruption of latent HIV in vivo during the clearance of actinic keratosis by ingenol mebutate.

Actinic keratosis (AK) is a precancerous skin lesion that is common in HIV-positive patients. Without effective treatment, AKs can progress to squamous cell carcinoma. Ingenol mebutate, a PKC agonist, is a US Food and Drug Administration-approved (FDA-approved) topical treatment for AKs. It can induce reactivation of latent HIV transcription in CD4+ T cells both in vitro and ex vivo. Although PKC agonists are known to be potent inducers of HIV expression from latency, their effects in vivo are not known because of the concerns of toxicity. Therefore, we sought to determine the effects of topical ingenol mebutate gel on the HIV transcription profile in HIV-infected individuals with AKs, specifically in the setting of suppressive antiretroviral therapy (ART). We found that AKs cleared following topical application of ingenol mebutate and detected marginal changes in immune activation in the peripheral blood and in skin biopsies. An overall increase in the level of HIV transcription initiation, elongation, and complete transcription was detected only in skin biopsies after the treatment. Our data demonstrate that application of ingenol mebutate to AKs in ART-suppressed HIV-positive patients can effectively cure AKs as well as disrupt HIV latency in the skin tissue microenvironment in vivo without causing massive immune activation.

[1]  H. Hatano,et al.  Gut and blood differ in constitutive blocks to HIV transcription, suggesting tissue-specific differences in the mechanisms that govern HIV latency , 2018, PLoS pathogens.

[2]  E. Stockfleth,et al.  Nonmelanoma skin cancer – from actinic keratosis to cutaneous squamous cell carcinoma , 2018, Journal der Deutschen Dermatologischen Gesellschaft = Journal of the German Society of Dermatology : JDDG.

[3]  J. Wong,et al.  HIV latency in isolated patient CD4+ T cells may be due to blocks in HIV transcriptional elongation, completion, and splicing , 2018, Science Translational Medicine.

[4]  D. Margolis,et al.  HIV latency is reversed by ACSS2-driven histone crotonylation , 2018, The Journal of clinical investigation.

[5]  I. Sadowski,et al.  Compounds producing an effective combinatorial regimen for disruption of HIV‐1 latency , 2017, EMBO molecular medicine.

[6]  T. Chun,et al.  In vivo activation of latent HIV with a synthetic bryostatin analog effects both latent cell "kick" and "kill" in strategy for virus eradication , 2017, PLoS pathogens.

[7]  C. Tepper,et al.  Oncolytic Reactivation of KSHV as a Therapeutic Approach for Primary Effusion Lymphoma , 2017, Molecular Cancer Therapeutics.

[8]  D. Hazuda,et al.  HDAC inhibition induces HIV-1 protein and enables immune-based clearance following latency reversal. , 2017, JCI insight.

[9]  J. Blankson,et al.  The effect of Ingenol-B on the suppressive capacity of elite suppressor HIV-specific CD8+ T cells , 2017, PloS one.

[10]  A. Rice,et al.  Assays for precise quantification of total (including short) and elongated HIV-1 transcripts. , 2017, Journal of Virological Methods.

[11]  M. Tremblay,et al.  HIV-1 Latency-Reversing Agents Prostratin and Bryostatin-1 Induce Blood–Brain Barrier Disruption/Inflammation and Modulate Leukocyte Adhesion/Transmigration , 2017, The Journal of Immunology.

[12]  Anna Kula,et al.  Reactivation capacity by latency-reversing agents ex vivo correlates with the size of the HIV-1 reservoir , 2017, AIDS.

[13]  R. Siliciano,et al.  Reactivation of simian immunodeficiency virus reservoirs in the brain of virally suppressed macaques , 2016, AIDS.

[14]  B. Walker,et al.  Single-Cell Characterization of Viral Translation-Competent Reservoirs in HIV-Infected Individuals. , 2016, Cell host & microbe.

[15]  H. Haenssle,et al.  Tumor-Preferential Induction of Immune Responses and Epidermal Cell Death in Actinic Keratoses by Ingenol Mebutate , 2016, PloS one.

[16]  B. Turkbey,et al.  Imaging lymphoid tissues in nonhuman primates to understand SIV pathogenesis and persistence. , 2016, Current opinion in virology.

[17]  J. Lifson,et al.  Defining HIV and SIV Reservoirs in Lymphoid Tissues , 2016, Pathogens & immunity.

[18]  Coral Barbas,et al.  Bryostatin-1 for latent virus reactivation in HIV-infected patients on antiretroviral therapy , 2016, AIDS.

[19]  Yuyang Tang,et al.  Synergistic Reactivation of Latent HIV Expression by Ingenol-3-Angelate, PEP005, Targeted NF-kB Signaling in Combination with JQ1 Induced p-TEFb Activation , 2015, PLoS pathogens.

[20]  C. Cook,et al.  The treatment of carcinoma in situ and squamous cell carcinoma of the conjunctiva with fractionated strontium-90 radiation in a population with a high prevalence of HIV , 2015, British Journal of Ophthalmology.

[21]  G. Jiang,et al.  Targeting NF-κB signaling with protein kinase C agonists as an emerging strategy for combating HIV latency. , 2015, AIDS research and human retroviruses.

[22]  A. Tanuri,et al.  Reactivation of HIV latency by a newly modified Ingenol derivative via protein kinase C&dgr;–NF-&kgr;B signaling , 2014, AIDS.

[23]  J. Wong,et al.  Advantages of using the QIAshredder instead of restriction digestion to prepare DNA for droplet digital PCR. , 2014, BioTechniques.

[24]  Neil Swanson,et al.  Ingenol mebutate gel for actinic keratosis. , 2012, The New England journal of medicine.

[25]  Mahendra Kumar,et al.  Human immunodeficiency virus type 1 RNA Levels in different regions of human brain: Quantification using real-time reverse transcriptase-polymerase chain reaction , 2011, Journal of NeuroVirology.

[26]  E. Maverakis,et al.  Light, including ultraviolet. , 2010, Journal of autoimmunity.

[27]  S. Ogbourne,et al.  PEP005 (ingenol mebutate) gel, a novel agent for the treatment of actinic keratosis: Results of a randomized, double‐blind, vehicle‐controlled, multicentre, phase IIa study , 2009, The Australasian journal of dermatology.

[28]  Jean Kanitakis,et al.  Detection of human immunodeficiency virus-DNA and RNA in the skin of HIV-infected patients using the polymerase chain reaction. , 1991, The Journal of investigative dermatology.